)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Lexicon Pharmaceuticals (LXRX) investor relations material
Lexicon Pharmaceuticals H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 27th Annual Global Investment Conference summary8 Sep, 2025
Portfolio and R&D pipeline progress
Focus shifted to core cardiometabolic R&D portfolio, with strong progress in 2023 and multiple late-stage assets advancing.
Pilibapadin completed phase 2 trials in diabetic peripheral neuropathic pain (DPNP) and post-herpetic neuralgia, with positive results and phase 3 preparation underway.
LX9851 R&D studies nearing completion, with a global license to Novo Nordisk for obesity and related conditions.
Sotagliflozin phase 3 SONATA trial for hypertrophic cardiomyopathy (HCM) is accelerating enrollment, with global expansion outside the U.S. and Europe.
Licensing strategy includes ex-U.S./EU deals with Vieitrace and ongoing partnering discussions for pilibapadin.
Clinical data and scientific validation
Pilibapadin demonstrated strong biological activity and clinical benefit in neuropathic pain, with a clear phase 3 dose and favorable safety profile.
Advisory board and scientific data support pilibapadin's differentiation, with three positive phase 2 trials and broad potential beyond neuropathic pain.
Preclinical data show pilibapadin's activity in chemotherapy-induced neuropathy and multiple sclerosis pain, suggesting further indication expansion.
Upcoming data presentations at major conferences (Neurodiab, AASD, Pain Therapeutic Summit) will showcase comprehensive phase 2 results.
Market opportunity and regulatory updates
Pilibapadin is positioned as a leading non-opioid oral candidate for DPNP, with potential to be the first approval in 20 years.
Sotagliflozin targets a large unmet need in HCM and HFpEF, with unique mechanisms and potential as a first-line agent due to recent ESC findings.
Beta blockers' efficacy in HCM is being questioned, increasing sotagliflozin's relevance.
SONATA and SOTA-CROSS trials address both obstructive and non-obstructive HCM, with complementary endpoints and strong enrollment trends.
Regulatory submissions for sotagliflozin in HFpEF are progressing, and additional data for Zynquista in type 1 diabetes have been submitted to the FDA.
Pilibapadin Phase 3: How to manage placebo?
SOTA's unique HCM mechanism and market impact?
Zynquista: Path via investigator-sponsored studies?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Lexicon Pharmaceuticals earnings date
Q3 202511 Nov, 2025
Next Lexicon Pharmaceuticals earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Lexicon Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of diseases with significant unmet medical needs. The company leverages its expertise in gene science to discover and develop small-molecule drugs aimed at addressing serious conditions such as heart disease, diabetes, and cancer. Lexicon's drug development approach involves targeting specific molecular pathways to create novel therapies that can alter the course of these diseases and improve patient outcomes. The company is headquartered in The Woodlands, Texas, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage